Dataset Viewer
Auto-converted to Parquet Duplicate
title
stringlengths
0
321
abstract
stringlengths
1.87k
5.66k
output_scheme
dict
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
BACKGROUND: Immune checkpoint inhibitors targeting PD-1 or CTLA-4 individually have shown substantial clinical benefits in the treatment of malignancies. We aimed to assess the safety and antitumour activity of cadonilimab monotherapy, a bispecific PD-1/CTLA-4 antibody, in patients with advanced solid tumours. METHODS:...
{ "metadata": { "trial_id": "NCT03852251", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 1b/2", "study_design": "not_specified", "blinding": "open_label", "years_of_enrollment": "Jan 18, 2019, and Jan 8, 2021" }, "population": { "disease": "solid tumours", "total_n...
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial
Background Tisotumab vedotin is a first-in-human antibody-drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is associated with poor clinical outcomes. We aimed to establish the safety, tolerability, pharmacokinetic profile, and antitumour activity of tisotumab vedo...
{ "metadata": { "trial_id": "NCT02001623", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 1-2", "study_design": "not_specified", "blinding": "open_label", "years_of_enrollment": "Oct 8, 2015, and April 26, 2018" }, "population": { "disease": "solid tumours", "total_...
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
BACKGROUND: In preliminary findings from the recurrent or metastatic cervical cancer cohort of CheckMate 358, nivolumab showed durable anti-tumour responses, and the combination of nivolumab plus ipilimumab showed promising clinical activity. Here, we report long-term outcomes from this cohort. METHODS: CheckMate 358 w...
{ "metadata": { "trial_id": "NCT02488759", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 1-2", "study_design": "randomized", "blinding": "open_label", "years_of_enrollment": "October, 2015, and March, 2020" }, "population": { "disease": "cervical cancer", "total_nu...
Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9-14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial
BACKGROUND: Human papillomavirus (HPV) vaccines have been available for nearly 20 years. However, the overall coverage of girls aged 15 years and younger is low, especially in low-resource settings, where the burden of cervical cancer is highest. Increasing access and facilitating implementation of HPV vaccination will...
{ "metadata": { "trial_id": "NCT04508309", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "open_label", "years_of_enrollment": "March 15 and Nov 18, 2021" }, "population": { "disease": "cervical cancer", "total_number_of...
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)
BACKGROUND: GOG 240 was a practice-changing randomised phase 3 trial that concluded that chemotherapy plus bevacizumab for advanced cervical cancer significantly improves overall and progression-free survival, and the proportion of patients achieving an overall objective response, compared with chemotherapy alone. In t...
{ "metadata": { "trial_id": "NCT00803062", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "open_label", "years_of_enrollment": "April 6, 2009, and Jan 3, 2012" }, "population": { "disease": "cervical cancer", "total_numb...
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial
BACKGROUND: The role of the neurokinin-1 (NK-1) receptor antagonists in the prevention of radiation-induced nausea and vomiting has not been established. The purpose of the GAND-emesis study was to investigate the efficacy and safety of fosaprepitant in combination with palonosetron and dexamethasone in the prevention ...
{ "metadata": { "trial_id": "NCT01074697", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "double_blind", "years_of_enrollment": "June 15, 2010, and March 8, 2015" }, "population": { "disease": "cervical cancer", "total_...
Continuous infusion of carboplatin during conventional radiotherapy treatment in advanced squamous carcinoma of the cervix uteri IIB-IIIB (UICC). A phase I/II and pharmacokinetic study
OBJECTIVE: A prospective, single-arm phase-I/II trial performed to assess the efficacy and toxicity of the concomitant use continuous infusion of low-dose carboplatin and pelvic conventional radiotherapy in patients with locally advanced squamous cell carcinoma of the cervix. MATERIALS AND METHODS: Between January and ...
{ "metadata": { "trial_id": "not_specified", "registry_source": "not_specified", "trial_phase": "phase I/II", "study_design": "single_arm", "blinding": "not_specified", "years_of_enrollment": "January and July 1994" }, "population": { "disease": "not_specified", "total_number_of_pa...
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial
Importance The KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful survival benefits with the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer. Treatment effects in patient subgroups o...
{ "metadata": { "trial_id": "NCT03635567", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "double_blind", "years_of_enrollment": "November 20, 2018, to May 3, 2021" }, "population": { "disease": "cervical cancer", "total...
Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix
Importance The evidence for concurrent chemoradiotherapy (CT-RT) in International Federation of Gynecology and Obstetrics (FIGO) stage IIIB squamous cell carcinoma of the uterine cervix is not robust. This study reports the final results of a randomized clinical trial of concurrent cisplatin-based CT-RT and radiotherap...
{ "metadata": { "trial_id": "NCT00193791", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "open_label", "years_of_enrollment": "between July 7, 2003, and September 22, 2011" }, "population": { "disease": "cervical cancer", ...
Abstract CT067: The anti-BCMA antibody-drug conjugate HDP-101 with a novel amanitin payload shows promising initial first in human results in relapsed multiple myeloma
Background: HDP-101 is a new antibody drug conjugatetargeting B-cell maturation antigen (BCMA) that carries a synthetic amanitin payload with a new mode of action. Amanitin inhibits RNA polymerase II, effectively stopping transcription and inducing apoptosis in tumor cells, regardless of their proliferation status. It'...
{ "metadata": { "trial_id": "not_specified", "registry_source": "not_specified", "trial_phase": "phase 1/2a", "study_design": "non_randomized", "blinding": "open_label", "years_of_enrollment": "November 2023" }, "population": { "disease": "not_specified", "total_number_of_patients"...
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
BACKGROUND: Few effective second-line treatments exist for women with recurrent or metastatic cervical cancer. Accordingly, we aimed to evaluate the efficacy and safety of tisotumab vedotin, a tissue factor-directed antibody-drug conjugate, in this patient population. METHODS: This multicentre, open-label, single-arm, ...
{ "metadata": { "trial_id": "NCT03438396", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 2", "study_design": "single_arm", "blinding": "open_label", "years_of_enrollment": "June 12, 2018, and April 11, 2019" }, "population": { "disease": "cervical cancer", "total_n...
Efficacy of Endostar plus concurrent chemoradiotherapy in locally advanced cervical cancer: a multicenter, phase II randomized trial
Background Cervical cancer remains the fourth most common malignant cancer in females and the fourth most common cause of mortality in women worldwide. Approximately 70% of new cases are diagnosed as locoregionally advanced cervical cancer (LACC), posing a significant threat to women's health. Concurrent chemoradiother...
{ "metadata": { "trial_id": "NCT03086681", "registry_source": "clinicaltrials.gov", "trial_phase": "phase II", "study_design": "randomized", "blinding": "open_label", "years_of_enrollment": "not_specified" }, "population": { "disease": "cervical cancer", "total_number_of_patients":...
A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104)
4596 Background: A majority of patients (pts) with bladder cancer present with non-muscle invasive disease; for pts with high-risk tumors, standard of care (SOC) is resection of tumor followed by intravesical Bacillus Calmette-Guerin (BCG). Once pts experience recurrence and develop BCG-unresponsive disease, SOC is rad...
{ "metadata": { "trial_id": "NCT05014139", "registry_source": "not_specified", "trial_phase": "phase 1", "study_design": "not_specified", "blinding": "open_label", "years_of_enrollment": "not_specified" }, "population": { "disease": "bladder cancer", "total_number_of_patients": "6"...
Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study
PURPOSE: Three previous mitomycin-cisplatin-based chemotherapy trials conducted within the EORTC Gynecological Cancer Cooperative Group (GCCG) in patients with disseminated squamous-cell carcinoma of the uterine cervix (SCCUC) suggested that with such regimens a higher overall response rate and a higher complete respon...
{ "metadata": { "trial_id": "not_specified", "registry_source": "not_specified", "trial_phase": "phase III", "study_design": "randomized", "blinding": "not_specified", "years_of_enrollment": "not_specified" }, "population": { "disease": "cervical cancer", "total_number_of_patients"...
An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE...
LBA5511 Background: In the last 2 decades, there has been a trend towards less radical surgery in patients with low-risk cervical cancer. Retrospective data suggested that less radical surgery may be safe and associated with less morbidity. The objective of this non-inferiority phase III prospective randomized trial wa...
{ "metadata": { "trial_id": "NCT01658930", "registry_source": "not_specified", "trial_phase": "phase III", "study_design": "randomized", "blinding": "not_specified", "years_of_enrollment": "December 2012 to November 2019" }, "population": { "disease": "cervical cancer", "total_numb...
First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC).
Background: CEACAM5 is a cell surface protein with limited expression in adult healthy tissues, but high expression in various adenocarcinomas, particularly in CRC (>90% of pts). M9140 is the first anti-CEACAM5 ADC with a topoisomerase 1 inhibitor (Top1i) payload (exatecan). The ß-glucuronide linker connecting the M914...
{ "metadata": { "trial_id": "NCT05464030", "registry_source": "not_specified", "trial_phase": "phase 1", "study_design": "randomized", "blinding": "not_specified", "years_of_enrollment": "not_specified" }, "population": { "disease": "colorectal cancer", "total_number_of_patients": ...
A phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC).
5066 Background: FOR46 is an MMAE-containing antibody-drug conjugate (ADC) targeting a tumor-specific conformational epitope on the extracellular domain of CD46 on prostate cancer and other cancer tissues in a lineage independent fashion. A prior phase 1, first-in-human trial of FOR46 demonstrated encouraging prelimina...
{ "metadata": { "trial_id": "NCT05011188", "registry_source": "not_specified", "trial_phase": "phase 1b", "study_design": "not_specified", "blinding": "not_specified", "years_of_enrollment": "not_specified" }, "population": { "disease": "prostate cancer", "total_number_of_patients"...
Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors
3002 Background: Tissue factor (TF) overexpression is associated with thrombosis, metastasis and poor prognosis in solid tumors, including cervical and pancreatic cancer. MRG004A is a novel anti-TF monoclonal antibody conjugated (ADC) to MMAE payload (drug-to-antibody ratio: 3.8), utilizing Glycoconnect site-specific c...
{ "metadata": { "trial_id": "NCT03941574", "registry_source": "not_specified", "trial_phase": "phase I/II", "study_design": "not_specified", "blinding": "not_specified", "years_of_enrollment": "not_specified" }, "population": { "disease": "solid tumors", "total_number_of_patients":...
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
BACKGROUND: At the first interim analysis of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, the addition of pembrolizumab to chemoradiotherapy provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with locally advanced cervical cancer. We report the over...
{ "metadata": { "trial_id": "NCT04221945", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "double_blind", "years_of_enrollment": "June 9, 2020, and Dec 15, 2022" }, "population": { "disease": "cervical cancer", "total_nu...
Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study
3037 Background: Prognosis for advanced pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer (BTC) remains poor, with limited treatment options available. Expression of claudin18.2 (CLDN18.2) has emerged as a potential target for anti-cancer treatment. Herein, we report preliminary safety and efficacy resul...
{ "metadata": { "trial_id": "NCT05458219", "registry_source": "not_specified", "trial_phase": "phase 1", "study_design": "not_specified", "blinding": "not_specified", "years_of_enrollment": "not_specified" }, "population": { "disease": "pancreatic and biliary tract cancer", "total_...
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
BACKGROUND: Concurrent chemoradiotherapy has been the standard of care for locally advanced cervical cancer for over 20 years; however, 30-40% of treated patients have recurrence or progression within 5 years. Immune checkpoint inhibition has improved outcomes for patients with PD-L1 positive metastatic or recurrent ce...
{ "metadata": { "trial_id": "not_specified", "registry_source": "not_specified", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "double_blind", "years_of_enrollment": "Feb 15, 2019, and Dec 10, 2020" }, "population": { "disease": "cervical cancer", "total_numbe...
Phase 1 trial of SHR-A2102, a nectin-4–directed antibody drug conjugate (ADC), in advanced solid tumors
Background: Nectin-4 is a cell adhesion molecule that is highly expressed in a wide variety of cancers and is associated with poor prognosis. SHR-A2102 is a novel ADC consisting of a fully humanized Nectin-4–directed monoclonal antibody, bound to topoisomerase I inhibitor payload via a cleavable linker. We conducted a ...
{ "metadata": { "trial_id": "NCT05701709", "registry_source": "not_specified", "trial_phase": "phase 1", "study_design": "not_specified", "blinding": "not_specified", "years_of_enrollment": "not_specified" }, "population": { "disease": "solid tumors", "total_number_of_patients": "3...
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
BACKGROUND PD-1 inhibitor plus chemotherapy had been shown to be an effective first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC). However, there was no robust evidence showing a PD-L1 inhibitor combined with chemotherapy benefited patients with squamous and non-squamous NSCLC. GEMSTONE...
{ "metadata": { "trial_id": "NCT03789604", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "double_blind", "years_of_enrollment": "Dec 13, 2018, and May 15, 2020" }, "population": { "disease": "NSCLC", "total_number_of_pa...
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
BACKGROUND: In the first interim analysis of the ORIENT-31 trial, compared with chemotherapy alone, sintilimab plus bevacizumab biosimilar IBI305 plus chemotherapy (pemetrexed and cisplatin) significantly improved progression-free survival in patients with EGFR-mutated non-squamous non-small-cell lung cancer (NSCLC) wh...
{ "metadata": { "trial_id": "not_specified", "registry_source": "not_specified", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "double_blind", "years_of_enrollment": "July 11, 2019, and March 31, 2022" }, "population": { "disease": "NSCLC", "total_number_of_pa...
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
BACKGROUND: GEMSTONE-302 was a phase 3 trial in patients with treatment-naive metastatic squamous or non-squamous non-small-cell lung cancer (NSCLC), showed significant improvement in progression-free survival and overall survival with sugemalimab, a PD-L1 inhibitor, plus chemotherapy versus placebo plus chemotherapy. ...
{ "metadata": { "trial_id": "NCT03789604", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "double_blind", "years_of_enrollment": "December 13, 2018, and May 15, 2020" }, "population": { "disease": "NSCLC", "total_number_...
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
BACKGROUND: Patients with resectable non-small-cell lung cancer (NSCLC), particularly those with EGFR mutations, face a high risk of recurrence and mortality post-surgery. Aumolertinib, a third-generation EGFR tyrosine-kinase inhibitor, is approved in China for adjuvant treatment in patients with NSCLC harbouring EGFR ...
{ "metadata": { "trial_id": "NCT04687241", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "double_blind", "years_of_enrollment": "April 30, 2021, and May 17, 2022" }, "population": { "disease": "NSCLC", "total_number_of_...
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
BACKGROUND: After a median follow-up of 18.3 months, the third-generation anaplastic lymphoma kinase (ALK) tyrosine-kinase inhibitor, lorlatinib, improved progression-free survival in patients with treatment-naive, ALK-positive non-small-cell lung cancer in the phase 3 CROWN study. Here we report updated efficacy data,...
{ "metadata": { "trial_id": "NCT03052608", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "open_label", "years_of_enrollment": "May 11, 2017, and Feb 28, 2019" }, "population": { "disease": "non-small-cell lung cancer", ...
Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study
Background Checkpoint inhibitors, including combinations with standard-of-care chemotherapy, have shown survival benefit in patients with metastatic non-small-cell lung cancer (NSCLC); however, access to these drugs varies. We aimed to evaluate the efficacy of the PD-1 inhibitor retifanlimab plus platinum-based chemoth...
{ "metadata": { "trial_id": "NCT04205812", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "double_blind", "years_of_enrollment": "Sept 11, 2020, and March 14, 2023" }, "population": { "disease": "NSCLC", "total_number_of...
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
BACKGROUND VEGF inhibitors can enhance the efficacy of immunotherapy. However, despite high initial response rates, almost all patients eventually develop treatment resistance to EGFR tyrosine-kinase inhibitors. We aimed to evaluate the efficacy and safety of sintilimab with or without IBI305 plus pemetrexed and cispla...
{ "metadata": { "trial_id": "NCT03802240", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "double_blind", "years_of_enrollment": "July 11, 2019, and July 31, 2021" }, "population": { "disease": "NSCLC", "total_number_of_...
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
BACKGROUND: Tumor Treating Fields (TTFields) are electric fields that disrupt processes critical for cancer cell survival, leading to immunogenic cell death and enhanced antitumour immune response. In preclinical models of non-small-cell lung cancer, TTFields amplified the effects of chemotherapy and immune checkpoint ...
{ "metadata": { "trial_id": "NCT02973789", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "open_label", "years_of_enrollment": "Feb 13, 2017, and Nov 19, 2021" }, "population": { "disease": "non-small-cell lung cancer", ...
Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)
Abstract Background: Almonertinib (HS-10296) is an oral, potent, high selective third generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) for sensitizing mutations and EGFR T790M mutation. The preliminary clinical data of almonertinib reported in WCLC showed favorable efficacy and safety in target populations. Here, w...
{ "metadata": { "trial_id": "NCT02981108", "registry_source": "not_specified", "trial_phase": "phase III", "study_design": "single_arm", "blinding": "double_blind", "years_of_enrollment": "May 2018 to October 2018" }, "population": { "disease": "NSCLC", "total_number_of_patients": ...
Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study
LBA9000 Background: EGFR TKIs are standard 1L therapy for metastatic NSCLC with sensitizing EGFR mutations; however, most patients (pts) ultimately experience PD. We report the protocol-specified final analysis (FA) from the randomized, double-blind, phase 3 KEYNOTE-789 study of pemetrexed (pem) and platinum-based chem...
{ "metadata": { "trial_id": "NCT03820986", "registry_source": "not_specified", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "double_blind", "years_of_enrollment": "not_specified" }, "population": { "disease": "NSCLC", "total_number_of_patients": "492" }, ...
Efficacy and safety of SMET12 in combination with toripalimab and chemotherapy in advanced non-small-cell lung cancer patients tested positive for EGFR protein who are treatment-naΓ―ve or harbor acquired resistance to standard therapy: a phase 2, multi-cohort clinical trial
Objective: SMET12 is a bispecific T-cell engager targeting epidermal growth factor receptor (EGFR) and CD3. This phase 2 clinical trial aimed to investigate the efficacy and safety of SMET12 plus toripalimab and chemotherapy among advanced non-small-cell lung cancer (NSCLC) patients tested positive for EGFR protein, in...
{ "metadata": { "trial_id": "NCT06208033", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 2", "study_design": "not_specified", "blinding": "not_specified", "years_of_enrollment": "not_specified" }, "population": { "disease": "NSCLC", "total_number_of_patients": "32"...
Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET -amplification (MET amp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study
Background: Savo, a highly selective MET-TKI, combined with osi, may overcome acquired MET-driven resistance in EGFRm advanced NSCLC after PD on EGFR-TKIs. Here we report primary results of the prespecified interim analysis (IA) in SACHI study, comparing efficacy and safety of savo + osi with chemo in this disease sett...
{ "metadata": { "trial_id": "NCT05015608", "registry_source": "not_specified", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "open_label", "years_of_enrollment": "15 Oct 2021 to 30 Aug 2024" }, "population": { "disease": "NSCLC", "total_number_of_patients": "2...
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials
IMPORTANCE: Brain metastases reduce overall survival rates of patients with non-small cell lung cancer (NSCLC); patients with epidermal growth factor receptor 2 (ERBB2 [formerly HER2])-mutant NSCLC are more likely to have baseline brain metastases. Trastuzumab deruxtecan (T-DXd) is an approved ERBB2-directed treatment ...
{ "metadata": { "trial_id": "not_specified", "registry_source": "not_specified", "trial_phase": "phase 2", "study_design": "randomized", "blinding": "open_label", "years_of_enrollment": "April 2023 to October 2024" }, "population": { "disease": "NSCLC", "total_number_of_patients": ...
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged β‰₯70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study
Background: Combined treatment with anti-PD-1 and anti-CTLA-4 antibodies has shown superiority over chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC), but data for older patients (aged β‰₯70 years) with an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1 or those with an ECOG pe...
{ "metadata": { "trial_id": "NCT03351361", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "open_label", "years_of_enrollment": "Feb 12, 2018, and Dec 15, 2020" }, "population": { "disease": "NSCLC", "total_number_of_pati...
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
BACKGROUND: Limertinib is a new third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This study aimed to prospectively assess the efficacy and safety of limertinib versus gefitinib as a first-line treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC) with EGFR-se...
{ "metadata": { "trial_id": "NCT04143607", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "double_blind", "years_of_enrollment": "Between June 30, 2021, and Sept 22, 2022" }, "population": { "disease": "NSCLC", "total_nu...
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
BACKGROUND: Furmonertinib (AST2818) is an irreversible, selective, third-generation EGFR tyrosine-kinase inhibitor. We aimed to investigate the efficacy and safety of furmonertinib versus the first-generation EGFR tyrosine-kinase inhibitor gefitinib as first-line treatment in patients with EGFR mutation-positive locall...
{ "metadata": { "trial_id": "NCT03787992", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "double_blind", "years_of_enrollment": "May 30, 2019, and Dec 5, 2019" }, "population": { "disease": "NSCLC", "total_number_of_pat...
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
BACKGROUND: Whether the addition of bevacizumab to a programmed cell death protein-1 (PD-1) inhibitor plus chemotherapy can provide further survival benefits as first-line treatment in non-squamous non-small-cell lung cancer (NSCLC) without EGFR sensitising mutations, or ALK/ROS1 rearrangements, is unknown. We evaluate...
{ "metadata": { "trial_id": "NCT03952403", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "double_blind", "years_of_enrollment": "Between Nov 25, 2019, and June 15, 2022" }, "population": { "disease": "NSCLC", "total_num...
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial
IMPORTANCE: The PACIFIC trial established durvalumab as the standard-of-care therapy for unresectable, stage III non-small cell lung cancer (NSCLC) without progression following concurrent chemoradiotherapy (cCRT). Novel immunotherapy combinations involving the anti-CD73 monoclonal antibody oleclumab or the anti-NKG2A ...
{ "metadata": { "trial_id": "NCT03822351", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 2", "study_design": "randomized", "blinding": "open_label", "years_of_enrollment": "January 2019 to July 2020" }, "population": { "disease": "NSCLC", "total_number_of_patients"...
BACKGROUND: Survival for non-small-cell lung cancer (NSCLC) remains unacceptably low, even in stage IA-IIA. Current guidelines recommend adjuvant treatment for patients considered to be at high risk in stages IB and IIA, but suggest criteria that have not been validated to predict benefit. A previously validated, CLIA-...
{ "metadata": { "trial_id": "NCT01817192", "registry_source": "clinicaltrials.gov", "trial_phase": "phase 3", "study_design": "randomized", "blinding": "not_specified", "years_of_enrollment": "Sept 11, 2020, and Feb 7, 2025" }, "population": { "disease": "NSCLC", "total_number_of_p...
First-in-class PD-1/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC)
Background: IBI363 is a first-in-class PD-1/IL-2Ξ±-bias bispecific antibody fusion protein to block PD-1 checkpoint and rejuvenate exhausted tumor-specific T cells by cis-activating Ξ±-bias IL-2. It has potential to address the unmet clinical need of patients (pts) with immunotherapy-resistant and cold tumors. Here, we r...
{ "metadata": { "trial_id": "NCT05460767", "registry_source": "not_specified", "trial_phase": "phase I", "study_design": "not_specified", "blinding": "not_specified", "years_of_enrollment": "not_specified" }, "population": { "disease": "NSCLC", "total_number_of_patients": "136" }...
Randomized phase II study of neoadjuvant (neoadj) anti-PD-1 dostarlimab (D) vs. D + anti-TIM-3 cobolimab (C) in high-risk resectable melanoma (mel) (NEO-MEL-T): Primary analysis
Background: Neoadj immunotherapy improves outcomes in high-risk resectable mel, although novel combinations that enhance efficacy while minimizing toxicity are needed. TIM-3 is highly expressed on dysfunctional CD8T cells and APCs within TME. Dual PD-1 and TIM-3 blockade promotes expansion and function of antigen-speci...
{ "metadata": { "trial_id": "NCT04139902", "registry_source": "not_specified", "trial_phase": "phase II", "study_design": "randomized", "blinding": "not_specified", "years_of_enrollment": "6/2020-11/2024" }, "population": { "disease": "melanoma", "total_number_of_patients": "57" ...
A phase II trial of pevonedistat plus docetaxel in patients with previously treated advanced non–small-cell lung cancer (NSCLC)
Background: For patients with stage IV NSCLC, treatment options are limited after progression on immunotherapy (IO) +/- platinum-based chemotherapy. Docetaxel alone or in combination with ramucirumab remains a standard of care, but response rates and survival benefit are suboptimal. Cullin-RING ligases (CRLs) catalyze ...
{ "metadata": { "trial_id": "NCT03228186", "registry_source": "not_specified", "trial_phase": "phase II", "study_design": "single_arm", "blinding": "not_specified", "years_of_enrollment": "3/5/2018 to 1/26/2021" }, "population": { "disease": "NSCLC", "total_number_of_patients": "31...
Long-term outcomes of postoperative radiotherapy for patients with pIIIA-N2 non-small-cell lung cancer after complete resection and adjuvant chemotherapy (PORT-C): a single-centre, randomized, phase 3 trial
Background The PORT-C trial was the first published phase III randomized clinical trial (RCT) to evaluate the role of postoperative radiotherapy (PORT) using intensity-modulated radiation therapy (IMRT)/three-dimensional conformal radiation therapy (3D-CRT) in patients with resected pIIIA-N2 non-small-cell lung cancer ...
{ "metadata": { "trial_id": "NCT00880971", "registry_source": "clinicaltrials.gov", "trial_phase": "phase III", "study_design": "randomized", "blinding": "not_specified", "years_of_enrollment": "January 1, 2009 and December 31, 2017" }, "population": { "disease": "non-small-cell lung c...
End of preview. Expand in Data Studio

Pharmacoeconomic Evidence Extraction Dataset

License

This dataset is released under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. You may use, share, and adapt the dataset provided that appropriate credit is given to the dataset authors.

For the full license terms, see the CC BY 4.0 license.

Overview

This dataset contains 250 expert-annotated records for research on automated extraction of structured pharmacoeconomic and clinical-trial evidence from published clinical trial reports.

The dataset was developed as part of the research study:

"Credibility-Aware Pharmacoeconomic Evidence Extraction from Clinical Trials via RAG-Enhanced Fine-Tuned Small Language Models"

Each record contains the publication title, abstract, and expert-produced structured annotations covering trial metadata, population characteristics, intervention/comparator arms, and reported outcomes.

Dataset Structure

The dataset is distributed in JSON Lines (.jsonl) format, with one JSON object per record. Each record follows a fixed structured format.

Record Format

{
  "trial_id": "PMID_XXXXXXXX",
  "title": "<clinical trial publication title>",
  "abstract": "<abstract text>",
  "labels": {
    "trial_metadata": {
      "registry_source": "<registry source>",
      "trial_phase": "<trial phase>",
      "study_design": "<study design>",
      "blinding": "<blinding status>",
      "years_of_enrollment": "<enrollment period>"
    },
    "population": {
      "disease": "<disease>",
      "total_number_of_patients": "<number of patients>"
    },
    "arms": [
      {
        "arm_name": "<arm name>",
        "arm_type": "<intervention/comparator/not_specified>"
      }
    ],
    "outcomes": [
      {
        "abbreviation": "<outcome abbreviation>",
        "expansion": "<outcome full name>"
      }
    ]
  }
}

The top-level trial_id identifies the source publication, while the remaining trial-level information is stored under labels.trial_metadata.

Annotation Schema

The annotation schema is grounded in the PICO framework (Population, Intervention, Comparator, Outcome), a standard framework used in clinical research and evidence synthesis. It is adapted here into a fixed, schema-constrained structure designed for structured pharmacoeconomic evidence extraction.

The schema was defined in collaboration with a pharmacoeconomic domain expert and implemented as a schema-validated Pydantic model. Each record therefore follows the same nested structure, regardless of the clinical trial design.

Schema Structure

Component PICO Mapping Field Type Allowed / Default Value
Trial Metadata Study context registry_source Constrained string clinicaltrials.gov / other / not_specified
trial_phase String None
study_design Constrained string randomized / non_randomized / single_arm / observational
blinding Constrained string open_label / single_blind / double_blind
years_of_enrollment String not_specified
Population Population disease String Required
total_number_of_patients String not_specified
Arms (1–5 per trial) Intervention / Comparator arm_name String Required
arm_type Constrained string intervention / comparator / not_specified
Outcomes (1–5 per trial) Outcome abbreviation String not_specified
expansion String Required

Every field has an explicit default or fallback value when the corresponding information is not stated in the source text. This allows the dataset to distinguish between information that is genuinely absent from the source and information that was missed during extraction.

Annotation Hierarchy

The structured annotations follow the hierarchy below:

Record
β”œβ”€β”€ trial_id
β”œβ”€β”€ title
β”œβ”€β”€ abstract
└── labels
    β”œβ”€β”€ trial_metadata
    β”‚   β”œβ”€β”€ registry_source
    β”‚   β”œβ”€β”€ trial_phase
    β”‚   β”œβ”€β”€ study_design
    β”‚   β”œβ”€β”€ blinding
    β”‚   └── years_of_enrollment
    β”œβ”€β”€ population
    β”‚   β”œβ”€β”€ disease
    β”‚   └── total_number_of_patients
    β”œβ”€β”€ arms
    β”‚   β”œβ”€β”€ arm_name
    β”‚   └── arm_type
    └── outcomes
        β”œβ”€β”€ abbreviation
        └── expansion

Annotation Methodology

The dataset was manually annotated by a pharmacoeconomic domain expert following a strict non-inferential extraction policy.

Only information explicitly stated in the source title or abstract was annotated. No inference, deduction, or external domain knowledge was used to complete missing fields. When information was not explicitly reported, the corresponding schema default or fallback value was assigned.

This annotation strategy ensures that the dataset distinguishes between:

  1. Information explicitly reported in the source.
  2. Information not reported in the source.
  3. Information that should not be inferred from contextual knowledge.

Expert annotation was selected instead of automated LLM-based annotation because preliminary evaluation showed that LLM-generated labels did not consistently satisfy the non-inferential annotation constraint, particularly for intervention/comparator arms and outcome-level fields.

Trial registry information was also not used as a substitute for the published abstract because registry records cannot always be reliably aligned with the exact version and content of the corresponding publication.

Intended Use

The dataset is intended for research and development in:

  • Pharmacoeconomic evidence extraction
  • Clinical trial information extraction
  • Structured medical information extraction
  • PICO-style information extraction
  • Retrieval-augmented generation (RAG)
  • Domain-specific small language models
  • Schema-constrained text generation
  • Evidence synthesis and decision-support research

Potential applications include:

  • Fine-tuning and evaluating language models for structured extraction from clinical trial abstracts
  • Benchmarking PICO-style extraction approaches
  • Developing retrieval and evidence-synthesis pipelines
  • Evaluating schema-constrained information extraction
  • Developing structured and auditable clinical-trial evidence extraction systems

The dataset was used in the associated study to train and evaluate fine-tuned small language models for pharmacoeconomic evidence extraction.

Data Sources

The records were derived from published clinical trial literature.

The dataset repository does not redistribute the full-text publications. It contains the publication title, abstract text, and expert-produced structured annotations.

The original publications remain subject to their respective copyright and licensing conditions. Users should obtain the original publications through the appropriate publisher, repository, or open-access source where available.

Ethical and Privacy Considerations

The dataset contains information derived from published clinical trial reports and does not intentionally include direct personal identifiers of individual patients.

The dataset is intended for research purposes and should not be used as a substitute for clinical judgment, regulatory assessment, or formal health technology assessment.

Limitations

The dataset has several limitations:

  • It contains 250 records, which limits its statistical power for large-scale benchmarking and may restrict the performance of models trained exclusively on this dataset.
  • The dataset represents the therapeutic area and clinical trial literature investigated in the associated study and may therefore not generalize to all therapeutic areas, diseases, trial designs, or publication formats.
  • The annotations are based on information explicitly available in the title and abstract. Consequently, information available only in the full text, tables, figures, supplementary materials, or trial registries is not necessarily represented.
  • The relatively small dataset size makes it more suitable for domain-specific experimentation and proof-of-concept research than for large-scale general-purpose model training.

Citation

If you use this dataset in your research, please cite the associated publication:

Youssef M, Mashaly M, Ashour M, El-Tayebi H.
Credibility-Aware Pharmacoeconomic Evidence Extraction from Clinical Trials via RAG-Enhanced Fine-Tuned Small Language Models.
[Publication details to be added after publication]

Acknowledgment

The dataset was developed as part of research on credibility-aware, retrieval-augmented, and fine-tuned small language models for pharmacoeconomic evidence extraction from clinical trial literature.

Downloads last month
48